Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
RATIONALE: Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis (TB) chemotherapy, but data regarding its activity in humans are limited. OBJECTIVES: Our objective was to compare the antimicrobial activity and safety of moxifloxacin versus isoniazid during the first 8 weeks of combination therapy for pulmonary TB. METHODS: Adults with sputum smear-positive pulmonary TB were randomly assigned to receive either moxifloxacin 400 mg plus isoniazid placebo, or isoniazid 300 mg plus moxifloxacin placebo, administered 5 days/week for 8 weeks, in addition to rifampin, pyrazinamide, and ethambutol. All doses were directly observed. Sputum was collected for culture every 2 weeks. The primary outcome was negative sputum culture at completion of 8 weeks of treatment. MEASUREMENTS AND MAIN RESULTS: Of 433 participants enrolled, 328 were eligible for the primary efficacy analysis. Of these, 35 (11%) were HIV positive, 248 (76%) had cavitation on baseline chest radiograph, and 213 (65%) were enrolled at African sites. Negative cultures at Week 8 were observed in 90/164 (54.9%) participants in the isoniazid arm, and 99/164 (60.4%) in the moxifloxacin arm (P = 0.37). In multivariate analysis, cavitation and enrollment at an African site were associated with lower likelihood of Week-8 culture negativity. The proportion of participants who discontinued assigned treatment was 31/214 (14.5%) for the moxifloxacin group versus 22/205 (10.7%) for the isoniazid group (RR, 1.35; 95% CI, 0.81, 2.25). CONCLUSIONS: Substitution of moxifloxacin for isoniazid resulted in a small but statistically nonsignificant increase in Week-8 culture negativity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
Outpatient gatifloxacin therapy and dysglycemia in older adults.
Park-Wyllie, L. Y., Juurlink, D. N., Kopp, A., Shah, B. R., Stukel, T. A., Stumpo, C., Dresser, L., Low, D. E., & Mamdani, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055191 · Cited by 367 · cited 1×
“University of California, San Diego Medical Center and collaborating site San Diego County Department of Health and Human Services, TB Control ( 12 ) Antonino Catanzaro, M.D., Kathleen S. Moser, M.D., Mark J. Tracy, M.D., Vivien Peach Francisco, R.N., Judy Davis, Sharon Reed, M.D., Christopher R. Peter, Ph.D.”
BackgroundRustomjee, R., Lienhardt, C., Kanyok, T. P., Davies, G., Levin, J., Mthiyane, T., Reddy, C., Sturm, A. W., Sirgel, F. A., Allen, J., et al. (2008) · PubMed · Cited by 326
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., O'Brien, R. J., Vernon, A. N., Chaisson, R. E., Bishai, W. R., & Grosset, J. H. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200310-1380oc · Cited by 314
Self-citationConde, M. B., Efron, A., Loredo, C., De Souza, G. R. M., Graça, N. P., Cezar, M. C., Ram, M., Chaudhary, M. A., Bishai, W. R., Kritski, A. L., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60333-0 · Cited by 289
Self-citationMoxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis
Burman, W. J., Goldberg, S., Johnson, J. L., Muzanye, G., Engle, M., Mosher, A. W., Choudhri, S., Daley, C. L., Munsiff, S. S., Zhao, Z., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200603-360oc · Cited by 286
Self-citationAssessment of New Sterilizing Drugs for Treating Pulmonary Tuberculosis by Culture at 2 Months
Mitchison, D. A. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/147.4.1062 · Cited by 215
Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model
Rosenthal, I. M., Zhang, M., Williams, K. N., Peloquin, C. A., Tyagi, S., Vernon, A. A., Bishai, W. R., Chaisson, R. E., Grosset, J. H., & Nuermberger, E. L. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040344 · Cited by 205
Self-citationShandil, R. K., Jayaram, R., Kaur, P., Gaonkar, S., Suresh, B. L., Mahesh, B. N., Jayashree, R., Nandi, V., Bharath, S., & Balasubramanian, V. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00414-06 · Cited by 203
Johnson, J. L., Hadad, D. J., Boom, W. H., Daley, C. L., Peloquin, C. A., Eisenach, K. D., Jankus, D. D., Debanne, S. M., Charlebois, E. D., Maciel, E. L. N., et al. (2006) · PubMed · Cited by 200
Self-citationHu, Y., Coates, A. R. M., & Mitchison, D. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.653-657.2003 · Cited by 187
Lubasch, A., Keller, I., Borner, K., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2600-2603.2000 · Cited by 186
Peloquin, C. A., Hadad, D. J., Molino, L. P. D., Palaci, M., Boom, W. H., Dietze, R., & Johnson, J. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01036-07 · Cited by 185
Self-citationMoxifloxacin (BAY12-8039), a New 8-Methoxyquinolone, Is Active in a Mouse Model of Tuberculosis
Miyazaki, E., Miyazaki, M., Chen, J. M., et al. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.1.85 · Cited by 145
Ball, P. D., Stahlmann, R., Kubin, R., Choudhri, S., & Owens, R. C. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90170-1 · Cited by 102
Self-citationShort-course therapy of acute cystitis: a brief review of therapeutic strategies
Tice, A. D. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.suppl_1.85 · Cited by 93
Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice
Lalande, V., Truffot-Pernot, C., Paccaly-Moulin, A., Grosset, J. H. E., & Ji, B. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.407 · Cited by 88
Self-citationAber, V. R., & Nunn, A. (1978) · PubMed · Cited by 65
Experimental Chemotherapy of Mycobacterial Diseases
Grosset, J. H. E., & Ji, B. (1998) · Springer eBooks · doi:10.1007/978-1-4615-7511-5_3 · Cited by 51
Self-citationHONGKONGCHESTSERVICEBRITISHME (1981) · The Lancet · doi:10.1016/s0140-6736(81)90057-x · Cited by 42
Gavin, J. R., Kubin, R., Choudhri, S., Kubitza, D., Himmel, H., Gross, R., & Meyer, J. M. (2004) · Drug Safety · doi:10.2165/00002018-200427090-00005 · Cited by 41
Self-citation
Cited by
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Self-citationFour-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Gillespie, S. H., Crook, A. M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murray, S. R., Pappas, F., Phillips, P. P. J., & Nunn, A. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407426 · Cited by 645
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Lee, M., Lee, J., Carroll, M. W., Choi, H., Min, S., Song, T., Via, L. E., Goldfeder, L. C., Kang, E., Jin, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201964 · Cited by 560
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
Dorman, S. E., Nahid, P., Kurbatova, E. V., Phillips, P. P. J., Bryant, K., Dooley, K. E., Engle, M., Goldberg, S. V., Phan, H. T. T., Hakim, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2033400 · Cited by 539
Self-citationBiomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice
Wallis, R. S., Pai, M., Menzies, D., Doherty, T. M., Walzl, G., Perkins, M. D., & Zumla, A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60359-5 · Cited by 453
Self-citation
Metadata
- Authors
- Dorman, S. E., Johnson, J. L., Goldberg, S., Muzanye, G., Padayatchi, N., Bozeman, L., Heilig, C. M., Bernardo, J., Choudhri, S., Grosset, J. H., Guy, E., Guyadeen, P., Leus, M. C., Maltas, G., Menzies, D., Nuermberger, E. L., Villarino, M., Vernon, A., Chaisson, R. E., & the Tuberculosis Trials Consortium
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08-01
- Volume
- 180
- Issue
- 3
- Pages
- 273-280
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2134527984
- Cited by
- 264
- References
- 21
- FWCI
- 22.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.